Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

June 27, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • ENGINEERED ONCOLYTIC ADENOVIRUS TO TREAT METASTATIC CANCER

None of the SARS-CoV-2 Genetic Mutations Appear to Increase Transmissibility

ICRISAT Biological Science Research Technician Vacancy Available

ENGINEERED ONCOLYTIC ADENOVIRUS TO TREAT METASTATIC CANCER
  • BiotechToday
  • World

ENGINEERED ONCOLYTIC ADENOVIRUS TO TREAT METASTATIC CANCER

bioxone December 2, 2020December 2, 2020

Husna, Amity University Kolkata

Oncolytic viruses are genetically engineered for the destruction of cancer or tumour-causing cells specifically. They’re delivered for treatment inside the body via intravenous injection. In 2015, one such oncolytic virus was approved by the FDA for treating skin cancer, melanoma. A major obstacle in the application of oncolytic adenoviruses is that they face a barrier from the human immune system. The antibodies and blood components neutralize the injected adenovirus doses and also send it to the liver, the body’s garbage disposal. Some patients also developed inflammation and infection reaction on the application of oncolytic adenovirus.

Recently these barriers have been overcome by the researchers from the Pharmacology department of Case Western Reserve University. They’ve re-engineered the human adenovirus in such a way that it doesn’t get caught by parts of the innate immune system easily. Dmitry Shayakhmetov, PhD has stated that now it is possible to deliver the modified virus systemically at possible high doses for suppression of the tumour growth and even the life-threatening systemic toxicities or inflammatory reaction won’t get triggered anymore. Furthermore, the re-engineered adenoviruses can be armed with genes and proteins that can stimulate an immunity to cancer. 

The re-engineered adenovirus is therefore a technology which can be customized for various cancer patients and can be used as personalized life-saving therapy to patients with metastatic cancer.  

Also read:None of the SARS-CoV-2 Genetic Mutations Appear to Increase Transmissibility

SOURCE: 

https://scitechdaily.com/new-weapon-against-metastatic-cancer-engineered-stealth-bomber-virus/

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged adenovirus cancer engineered oncolytic adenovirus FDA infections inflammation inflammatory reactions injection innate immune system intravenously melanoma metastasis metastatic cancer oncolytic patients skin cancer technology therapy tumour cells tumour growth weapon

4 thoughts on “ENGINEERED ONCOLYTIC ADENOVIRUS TO TREAT METASTATIC CANCER”

  1. Diwita Roy says:
    December 2, 2020 at 4:00 pm

    Very well written. Illuminating content.

    Reply
  2. Pingback: DRY SWAB-DIRECT RT-PCR TO RAMP UP TEST FREQUENCY - BioXone
  3. sania says:
    December 3, 2020 at 11:23 am

    👍well written

    Reply
  4. Fathima Nifara says:
    December 7, 2020 at 1:54 pm

    As Iam very much interested in cancer biology, I personally like this article and its written in a very comprehensible manner.

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Job and Internship
  • Signaling Pathway

ICRISAT Biological Science Research Technician Vacancy Available

bioxone December 3, 2020

-Shristi Sharma, Team bioXone ICRISAT Biological Science Research Technician Vacancy Available. ICRISAT hiring for research vacancies for BSc Biological Sciences candidates with mentioned qualifications are eligible. Check out all the details posted below on the same:  Name of Job: Research Technician No. of Posts: 01 How to Apply: Candidates should apply on or before 17 […]

Related Post

  • BiotechToday
  • World

Expert review over deaths reported in Europe following COVID19 vaccination

bioxone February 6, 2021February 6, 2021

Rohit Bhattacharjee, Amity University, Kolkata. The GACVS COVID-19 Vaccine Safety subcommittee met virtually on Tuesday, January 2021, to review available information and data of mortalities reported in frail, elderly individuals who had received the Pfizer BioNTech COVID-19 mRNA vaccine, BNT162b2 (hereafter, BNT162b2). Experts invited from the European Medicines Agency (EMA) and therefore the Uppsala Monitoring […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

AXL receptor: a new companion of the ACE2 receptor which helps SARS-CoV-2 to enter the human body

bioxone January 16, 2021January 16, 2021

Parnad Basu, Amity University Kolkata The pandemic caused by COVID-19 is continuing still. The causative viral pathogen of COVID-19 is SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). This SARS-CoV-2 actually belongs to the β coronavirus genus along with SARS-CoV (severe acute respiratory syndrome coronavirus) and MERS-CoV (middle east respiratory syndrome coronavirus). Although SARS-CoV-2 targets the […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

A Goldilocks Zone on Earth: Phytoplankton factory in Sea

bioxone January 18, 2021January 18, 2021

Sampriti Roy, University of Calcutta If we notice the beautiful colour gradients across the image above, we would find bright green along with bluer areas. These areas altogether presented a very interesting finding detected initially by satellite images in late 2020. Colourful signatures of plankton blooms in Grande Bay, off of Argentina’s Santa Cruz province […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy